Cerity Partners LLC Has $69.17 Million Stock Position in Danaher Corporation (NYSE:DHR)

Cerity Partners LLC lifted its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 11.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 337,409 shares of the conglomerate's stock after acquiring an additional 35,712 shares during the quarter. Cerity Partners LLC's holdings in Danaher were worth $69,170,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Vision Capital Management Inc. purchased a new stake in shares of Danaher in the first quarter valued at $461,000. Telos Capital Management Inc. lifted its holdings in shares of Danaher by 0.6% in the first quarter. Telos Capital Management Inc. now owns 45,281 shares of the conglomerate's stock valued at $9,283,000 after purchasing an additional 250 shares in the last quarter. Capital Insight Partners LLC lifted its holdings in shares of Danaher by 6.2% in the first quarter. Capital Insight Partners LLC now owns 3,698 shares of the conglomerate's stock valued at $758,000 after purchasing an additional 216 shares in the last quarter. First Interstate Bank lifted its holdings in shares of Danaher by 2.4% in the first quarter. First Interstate Bank now owns 3,533 shares of the conglomerate's stock valued at $724,000 after purchasing an additional 82 shares in the last quarter. Finally, Banque Pictet & Cie SA lifted its holdings in shares of Danaher by 181.9% in the first quarter. Banque Pictet & Cie SA now owns 54,644 shares of the conglomerate's stock valued at $11,202,000 after purchasing an additional 35,262 shares in the last quarter. 79.05% of the stock is owned by institutional investors.

Insider Activity

In related news, Chairman Steven M. Rales sold 1,250,000 shares of the business's stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the transaction, the chairman directly owned 3,105,808 shares in the company, valued at $611,036,665.92. The trade was a 28.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Christopher Paul Riley sold 15,805 shares of the business's stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total value of $3,129,390.00. Following the transaction, the executive vice president owned 15,179 shares in the company, valued at $3,005,442. This represents a 51.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 11.10% of the company's stock.

Danaher Stock Performance

Shares of Danaher stock traded down $0.71 during trading on Friday, reaching $204.80. The company's stock had a trading volume of 2,369,010 shares, compared to its average volume of 3,504,283. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.43. The business's fifty day moving average price is $196.05 and its 200-day moving average price is $206.47. The firm has a market cap of $146.57 billion, a price-to-earnings ratio of 39.77, a price-to-earnings-growth ratio of 2.89 and a beta of 0.77. Danaher Corporation has a one year low of $171.00 and a one year high of $281.70.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, topping analysts' consensus estimates of $1.62 by $0.26. The business had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.58 billion. Danaher had a return on equity of 10.80% and a net margin of 15.81%. As a group, equities research analysts predict that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.63%. Danaher's dividend payout ratio is 24.85%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Bank of America reduced their target price on Danaher from $265.00 to $230.00 in a report on Monday, April 14th. Citigroup restated a "buy" rating on shares of Danaher in a report on Monday, April 7th. JPMorgan Chase & Co. reduced their target price on Danaher from $280.00 to $260.00 and set an "overweight" rating for the company in a report on Tuesday, April 22nd. Leerink Partners increased their price objective on Danaher from $225.00 to $230.00 and gave the stock an "outperform" rating in a report on Wednesday, April 23rd. Finally, Scotiabank upgraded Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price objective for the company in a report on Friday. Three investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $248.43.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.